Clinical Trial

Treatment of Ulcerative Colitis

Study Description

A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Study M15-722 is a Phase 2a study to investigate the efficacy and safety of ABBV-323 in participants with moderate to severe UC who failed prior therapy.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - ABBV-323 Dose A

ABBV-323 Dose A is intravenously (IV) administered.

Drug - ABBV-323 Dose B

ABBV-323 Dose B is administered subcutaneously (SC).

Additional Information

Official Study Title

A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of ABBV-323 in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Clinical Trial ID

NCT03695185

ParticipAid ID

e73pje